Galectin Therapeutics (GALT) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 136.2% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -41.8% for GLSI. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $271.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | GLSI |
|---|---|---|
| Share price | $2.69 | $19.25 |
| Market cap | $271.35M | $282.56M |
| 1-day change | -4.27% | -2.73% |
| YTD return | -35.34% | -8.38% |
| 1-year return | -49.72% | +136.20% |
| 5-year return | +4.67% | -41.84% |
| EPS (TTM) | $-0.32 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-30.84M | $-19.36M |
| 52-week high | $7.13 | $34.10 |
| 52-week low | $2.03 | $7.78 |
| Distance from 52-week high | -62.27% | -43.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.92% | +198.70% |
| Average volume | 252.31K | 160.76K |
| Shares outstanding | 100.88M | 14.68M |
| Employees | 9 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed GALT by 185.9 percentage points over the past year.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
GALT vs GLSI FAQ
Which is bigger, Galectin Therapeutics or Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $271.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, GALT or GLSI?
GLSI returned +136.20% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.